Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-26T18:20:05.795Z Has data issue: false hasContentIssue false
  • English
  • Français

P0015 - Reduction in brain atrophy associated with Ethyl-Eicosapentaenoic Acid in Patients with Huntington's disease

Published online by Cambridge University Press:  16 April 2020

B.K. Puri ,
G.M. Bydder ,
A. Clarke ,
M.S. Manku  and
C.F. Beckmann
B.K. Puri
Affiliation:
MRI Unit, Imaging Sciences Department, MRC CSC, Imperial College London, Hammersmith Hospital, London, UK
G.M. Bydder
Affiliation:
Department of Radiology, University of California, San Diego, School of Medicine, San Diego, CA, USA
A. Clarke
Affiliation:
Amarin Neuroscience Limited, The Oxford Science Park, Oxford, UK
M.S. Manku
Affiliation:
Amarin Neuroscience Limited, The Oxford Science Park, Oxford, UK
C.F. Beckmann
Affiliation:
Clinical Neuroscience Department, Imperial College London and FMRIB Centre, University of Oxford, Oxford, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and Aims:

Ultra-pure ethyl-EPA, a semi-synthetic, ethyl ester of eicosapentaenoic acid, is associated with clinical improvement in motor functioning in Huntington's disease. The aim was to determine the extent to which it might reduce the rate of progress of cerebral atrophy.

Methods:

High-resolution MRIs were acquired at baseline, six months and one year in 30 patients with stage I or II Huntington's disease who took part in a randomized, double-blind, placebo-controlled trial of 2 g daily ethyl-EPA. For each subject and each pair of T1 images, the two-timepoint percentage brain volume change was estimated in a double-blind fashion using SIENA (Structural Image Evaluation, using Normalisation, of Atrophy), Version 2.5, part of FSL (version 4.0, http://www.fmrib.ox.ac.uk/fsl).

Results:

Figure 1 shows areas of significant group-level reduction in brain atrophy between patients receiving ethyl-EPA and those receiving placebo (red-yellow: the colour bar shows the p-value under the null hypothesis of no change). Significant changes are observed at the head of the caudate and the posterior section of the thalamus.

Conclusion:

Treatment with ethyl-EPA is associated with significant reduction in brain atrophy in Huntington's disease, particularly in the caudate and thalamus. No other drug tested in Huntington's disease has shown this effect (fx).

Type
Poster Session II: Alzheimer Disease and Dementia
Information
European Psychiatry , Volume 23 , Issue S2: 16th AEP Congress - Abstract book - 16th AEP Congress , April 2008 , pp. S196
Copyright
Copyright © European Psychiatric Association 2008
Submit a response

Comments

No Comments have been published for this article.